Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma.

Lesokhin AM, Bal S, Badros AZ.

Cancer Immunol Res. 2019 Aug;7(8):1224-1229. doi: 10.1158/2326-6066.CIR-19-0148. Review.

PMID:
31371317
2.

Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma.

Stadtmauer EA, Faitg TH, Lowther DE, Badros AZ, Chagin K, Dengel K, Iyengar M, Melchiori L, Navenot JM, Norry E, Trivedi T, Wang R, Binder GK, Amado R, Rapoport AP.

Blood Adv. 2019 Jul 9;3(13):2022-2034. doi: 10.1182/bloodadvances.2019000194.

3.

Characteristics and outcomes of therapy-related myeloid neoplasms after treatment for multiple myeloma.

Duong VH, Holtzman NG, Koka R, Singh ZN, Zou Y, Emadi A, Rapoport AP, Kocoglu MH, Baer MR, Badros AZ.

Leuk Lymphoma. 2019 Jul 8:1-4. doi: 10.1080/10428194.2019.1633639. [Epub ahead of print] No abstract available.

PMID:
31282234
4.

Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma.

Badros AZ, Ma N, Rapoport AP, Lederer E, Lesokhin AM.

Blood Adv. 2019 Jun 11;3(11):1658-1660. doi: 10.1182/bloodadvances.2019000191. No abstract available.

5.

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.

Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Grant S, Holkova B.

Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):569-575.e1. doi: 10.1016/j.clml.2018.05.023. Epub 2018 Jun 6.

PMID:
30122201
6.

Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival.

Hari P, Reece DE, Randhawa J, Flomenberg N, Howard DS, Badros AZ, Rapoport AP, Meisenberg BR, Filicko-Ohara J, Phillips GL, Vesole DH.

Bone Marrow Transplant. 2019 Feb;54(2):293-299. doi: 10.1038/s41409-018-0261-y. Epub 2018 Jun 15.

PMID:
29907806
7.

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.

Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM.

Leukemia. 2017 Nov;31(11):2443-2448. doi: 10.1038/leu.2017.138. Epub 2017 May 12.

PMID:
28620163
8.

Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).

Treon SP, Meid K, Tripsas C, Heffner LT, Eradat H, Badros AZ, Xu L, Hunter ZR, Yang G, Patterson CJ, Gustine J, Castillo JJ, Matous J, Ghobrial IM.

Clin Cancer Res. 2017 May 15;23(10):2400-2404. doi: 10.1158/1078-0432.CCR-16-1918. Epub 2016 Nov 11.

9.

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.

Lee SJ, Levitsky K, Parlati F, Bennett MK, Arastu-Kapur S, Kellerman L, Woo TF, Wong AF, Papadopoulos KP, Niesvizky R, Badros AZ, Vij R, Jagannath S, Siegel D, Wang M, Ahmann GJ, Kirk CJ.

Br J Haematol. 2016 Jun;173(6):884-95. doi: 10.1111/bjh.14014. Epub 2016 Apr 12.

10.

Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation.

Yared JA, Hardy N, Singh Z, Hajj S, Badros AZ, Kocoglu M, Yanovich S, Sausville EA, Ujjani C, Ruehle K, Goecke C, Landau M, Rapoport AP.

Bone Marrow Transplant. 2016 Jun;51(6):850-2. doi: 10.1038/bmt.2015.346. Epub 2016 Feb 1. No abstract available.

PMID:
26828905
11.

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.

Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann M, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala H, Hogan KT, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan D, Landgren O, Grant S.

Clin Cancer Res. 2016 Mar 1;22(5):1067-75. doi: 10.1158/1078-0432.CCR-15-1076. Epub 2015 Oct 7.

12.

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH.

Nat Med. 2015 Aug;21(8):914-921. doi: 10.1038/nm.3910. Epub 2015 Jul 20.

13.

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, Haideri NA, Yacoub A, Hess G, Lentzsch S, Spicka I, Chanan-Khan AA, Raab MS, Tarantolo S, Vij R, Zonder JA, Huang X, Jayabalan D, Di Liberto M, Huang X, Jiang Y, Kim ST, Randolph S, Chen-Kiang S.

Leuk Lymphoma. 2015;56(12):3320-8. doi: 10.3109/10428194.2015.1030641. Epub 2015 May 15.

PMID:
25813205
14.

Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study.

Bhatnagar V, Wu Y, Goloubeva OG, Ruehle KT, Milliron TE, Harris CG, Rapoport AP, Yanovich S, Sausville EA, Baer MR, Badros AZ.

Cancer. 2015 Apr 1;121(7):1064-70. doi: 10.1002/cncr.29160. Epub 2014 Dec 2.

15.

A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma.

Bao T, Goloubeva O, Pelser C, Porter N, Primrose J, Hester L, Sadowska M, Lapidus R, Medeiros M, Lao L, Dorsey SG, Badros AZ.

Integr Cancer Ther. 2014 Sep;13(5):396-404. doi: 10.1177/1534735414534729. Epub 2014 May 26.

16.

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K, Lonial S.

Haematologica. 2013 Nov;98(11):1753-61. doi: 10.3324/haematol.2013.089334. Epub 2013 Aug 9.

17.

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.

Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R.

Leukemia. 2013 Aug;27(8):1707-14. doi: 10.1038/leu.2013.29. Epub 2013 Jan 31.

18.

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, LeLeu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Bladé J, Orlowski RZ, Shah JJ; International Myeloma Working Group.

Leukemia. 2013 Apr;27(4):780-91. doi: 10.1038/leu.2012.336. Epub 2012 Nov 21. Review.

19.

Lenalidomide in myeloma--a high-maintenance friend.

Badros AZ.

N Engl J Med. 2012 May 10;366(19):1836-8. doi: 10.1056/NEJMe1202819. No abstract available.

PMID:
22571206
20.

Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.

Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, Albitar M, Berman D, Messina M, Anderson KC.

Br J Haematol. 2010 Aug;150(4):428-37. doi: 10.1111/j.1365-2141.2010.08264.x. Epub 2010 Jul 7.

21.

Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.

Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD, Badros AZ, Popplewell L, Coutre S, Fox JA, Mahadocon K, Chen T, Kegley P, Hoch U, Wierda WG.

J Clin Oncol. 2010 Jun 20;28(18):3015-22. doi: 10.1200/JCO.2009.26.1347. Epub 2010 May 17.

22.

In the age of novel therapies, what defines high-risk multiple myeloma?

Badros AZ.

J Natl Compr Canc Netw. 2010 Feb;8 Suppl 1:S28-34.

PMID:
20141672
23.

The role of maintenance therapy in the treatment of multiple myeloma.

Badros AZ.

J Natl Compr Canc Netw. 2010 Feb;8 Suppl 1:S21-7.

PMID:
20141671
25.

Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support.

Paul B, Trovato JA, Thompson J, Badros AZ, Goloubeva O.

J Oncol Pharm Pract. 2010 Mar;16(1):45-51. doi: 10.1177/1078155209105399. Epub 2009 Jun 12.

PMID:
19525301
26.

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.

Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R, Kenvin L, Yu Z, Olesnyckyj M, Zeldis J, Knight R, Anderson KC.

Blood. 2009 Jul 23;114(4):772-8. doi: 10.1182/blood-2008-12-196238. Epub 2009 May 26.

27.

PET/CT and MR imaging in myeloma.

Mulligan ME, Badros AZ.

Skeletal Radiol. 2007 Jan;36(1):5-16. Epub 2006 Aug 17. Review.

PMID:
16915386
28.

Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma.

Breyer RJ 3rd, Mulligan ME, Smith SE, Line BR, Badros AZ.

Skeletal Radiol. 2006 Sep;35(9):632-40. Epub 2006 Jun 7.

PMID:
16758246
29.

Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.

Badros AZ, Goloubeva O, Rapoport AP, Ratterree B, Gahres N, Meisenberg B, Takebe N, Heyman M, Zwiebel J, Streicher H, Gocke CD, Tomic D, Flaws JA, Zhang B, Fenton RG.

J Clin Oncol. 2005 Jun 20;23(18):4089-99. Epub 2005 May 2.

PMID:
15867202
30.

Multiple myeloma presenting initially as a solitary pleural effusion later complicated by malignant plasmacytic ascites.

Inoue Y, Chua K, McClure RF, Jimenez MC, Gocke CD, Badros AZ, Takebe N.

Leuk Res. 2005 Jun;29(6):715-8. Epub 2005 Apr 20.

PMID:
15863214
31.

Case 38-2004: a large tumor of the skull.

Badros AZ.

N Engl J Med. 2005 Apr 14;352(15):1610; author reply 1610. No abstract available.

PMID:
15829549
32.

Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.

Phillips GL, Meisenberg BR, Reece DE, Adams VR, Badros AZ, Brunner JL, Fenton RG, Filicko J, Grosso DL, Hale GA, Howard DS, Johnson VP, Kniska A, Marshall KW, Mookerjee B, Nath R, Rapoport AP, Sarkodee-Adoo C, Takebe N, Vesole DH, Wagner JL, Flomenberg N.

Bone Marrow Transplant. 2004 Apr;33(8):781-7.

PMID:
14767498
33.

Hypothyroidism in patients with multiple myeloma following treatment with thalidomide.

Badros AZ, Siegel E, Bodenner D, Zangari M, Zeldis J, Barlogie B, Tricot G.

Am J Med. 2002 Apr 1;112(5):412-3. No abstract available.

PMID:
11904117

Supplemental Content

Loading ...
Support Center